187 related articles for article (PubMed ID: 6871479)
1. Estrogen and progesterone receptor profile patterns in primary breast cancer.
Thorpe SM; Rose C; Pedersen BV; Rasmussen BB
Breast Cancer Res Treat; 1983; 3(1):103-10. PubMed ID: 6871479
[TBL] [Abstract][Full Text] [Related]
2. [Factors affecting estrogen and progesterone receptors in primary breast cancer].
Kuno K; Fukami A; Hori M; Kasumi F; Yoshimoto K
Gan No Rinsho; 1983 May; 29(6):621-7. PubMed ID: 6876431
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of steroid hormone receptors: multivariate analysis of systemically untreated patients with node negative primary breast cancer.
Thorpe SM; Rose C; Rasmussen BB; Mouridsen HT; Bayer T; Keiding N
Cancer Res; 1987 Nov; 47(22):6126-33. PubMed ID: 3664512
[TBL] [Abstract][Full Text] [Related]
4. Distribution, frequency, and quantitative analysis of estrogen, progesterone, androgen, and glucocorticoid receptors in human breast cancer.
Allegra JC; Lippman ME; Thompson EB; Simon R; Barlock A; Green L; Huff KK; Do HM; Aitken SC
Cancer Res; 1979 May; 39(5):1447-54. PubMed ID: 427788
[TBL] [Abstract][Full Text] [Related]
5. Estrogen and progesterone receptor determinations in breast cancer. Technology, biology and clinical significance.
Thorpe SM
Acta Oncol; 1988; 27(1):1-19. PubMed ID: 3284552
[TBL] [Abstract][Full Text] [Related]
6. Oestrogen and progesterone receptor determinations in breast cancer: technology and biology.
Thorpe SM; Rose C
Cancer Surv; 1986; 5(3):505-25. PubMed ID: 3555780
[TBL] [Abstract][Full Text] [Related]
7. Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays.
Regan MM; Viale G; Mastropasqua MG; Maiorano E; Golouh R; Carbone A; Brown B; Suurküla M; Langman G; Mazzucchelli L; Braye S; Grigolato P; Gelber RD; Castiglione-Gertsch M; Price KN; Coates AS; Goldhirsch A; Gusterson B;
J Natl Cancer Inst; 2006 Nov; 98(21):1571-81. PubMed ID: 17077359
[TBL] [Abstract][Full Text] [Related]
8. [Clinical and methodological considerations in the quantification of estrogen and progesterone receptors using monoclonal antibodies in breast cancer].
Navarro MA; Huguet J; Valero J; Samaniego JM; Rosel P; Sirvent JJ
Med Clin (Barc); 1991 Jun; 97(2):41-4. PubMed ID: 1895780
[TBL] [Abstract][Full Text] [Related]
9. Estrogen and progesterone receptors as prognostic factors in breast cancer.
Brdar B; Graf D; Padovan R; Nola P; Rudan N; Petrinec Z; Sarcević B; Belicza M
Tumori; 1988 Feb; 74(1):45-52. PubMed ID: 3354064
[TBL] [Abstract][Full Text] [Related]
10. Estrogen receptor negative and progesterone receptor positive primary breast cancer: pathological characteristics and clinical outcome. Institut Curie Breast Cancer Study Group.
Bernoux A; de Cremoux P; Lainé-Bidron C; Martin EC; Asselain B; Magdelénat H
Breast Cancer Res Treat; 1998 Jun; 49(3):219-25. PubMed ID: 9776505
[TBL] [Abstract][Full Text] [Related]
11. Differential expression of progesterone receptor, FOXA1, GATA3, and p53 between pre- and postmenopausal women with estrogen receptor-positive breast cancer.
Hosoda M; Yamamoto M; Nakano K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
Breast Cancer Res Treat; 2014 Apr; 144(2):249-61. PubMed ID: 24549642
[TBL] [Abstract][Full Text] [Related]
12. Hormonal receptor determination of 1,052 Chinese breast cancers.
Chow LW; Ho P
J Surg Oncol; 2000 Nov; 75(3):172-5. PubMed ID: 11088048
[TBL] [Abstract][Full Text] [Related]
13. Factors associated with prognosis in human breast cancer. IV. Progesterone receptors and clinical factors.
Macías A; Pascual MR; Pérez R; Lage A
Neoplasma; 1983; 30(5):593-601. PubMed ID: 6656963
[TBL] [Abstract][Full Text] [Related]
14. Estrogen receptor positive operable breast cancer: does menopausal status impact on HER2 and progesterone receptor status?
Wang N; Wang B; Wang Y; Hu J
Breast; 2011 Dec; 20(6):519-24. PubMed ID: 21700456
[TBL] [Abstract][Full Text] [Related]
15. [Studies on estrogen and progesterone receptors in human breast cancer by sucrose gradient centrifugation (author's transl)].
Iino Y
Nihon Naibunpi Gakkai Zasshi; 1979 Aug; 55(8):971-93. PubMed ID: 488478
[TBL] [Abstract][Full Text] [Related]
16. Menopausal status and cut off levels of steroid receptor ligand binding assays in breast cancer.
Norgren A; Forsberg AH; Lindgren A; Sällström JF
Anticancer Res; 1989; 9(1):173-6. PubMed ID: 2495752
[TBL] [Abstract][Full Text] [Related]
17. Changing estrogen and progesterone receptor patterns in breast carcinoma during the menstrual cycle and menopause.
Pujol P; Daures JP; Thezenas S; Guilleux F; Rouanet P; Grenier J
Cancer; 1998 Aug; 83(4):698-705. PubMed ID: 9708933
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of estrogen and progesterone receptors in stage II breast cancer.
Rydén S; Fernö M; Borg A; Hafström L; Möller T; Norgren A
J Surg Oncol; 1988 Apr; 37(4):221-6. PubMed ID: 3283457
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical determination of estrogen and progesterone receptors in breast cancer: relationship with clinicopathologic factors in 302 patients in Ivory Coast.
Effi AB; Aman NA; Koui BS; Koffi KD; Traoré ZC; Kouyate M
BMC Cancer; 2017 Feb; 17(1):115. PubMed ID: 28173783
[TBL] [Abstract][Full Text] [Related]
20. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
